We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amedisys (AMED) Catches Eye: Stock Gains 6.2% in Session
Read MoreHide Full Article
Amedisys, Inc. (AMED - Free Report) was a big mover last session, as its shares rose over 6% on the day. The move came after the company reported an earnings beat in fourth-quarter 2016 results. This also led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 12% in the past one-month time frame.
The company has seen one positive and one negative estimate revision in the past 30 days, while its Zacks Consensus Estimate remained unchanged over the same timeframe. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Amedisys currently carries a Zacks Rank #3 (Hold).
Is AMED going up? Or down? Predict to see what others think: Up or Down
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? Last year's market-beating Top 10 portfolio produced 5 double-digit winners. For example, oil and natural gas giant Pioneer Natural Resources and First Republic Bank racked up stellar gains of +44.9% and +44.3% respectively. Now a brand-new list for 2017 has been hand-picked from 4,400 companies covered by the Zacks Rank. See the 2017 Top 10 right now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amedisys (AMED) Catches Eye: Stock Gains 6.2% in Session
Amedisys, Inc. (AMED - Free Report) was a big mover last session, as its shares rose over 6% on the day. The move came after the company reported an earnings beat in fourth-quarter 2016 results. This also led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 12% in the past one-month time frame.
The company has seen one positive and one negative estimate revision in the past 30 days, while its Zacks Consensus Estimate remained unchanged over the same timeframe. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Amedisys currently carries a Zacks Rank #3 (Hold).
Amedisys Inc Price
Amedisys Inc Price | Amedisys Inc Quote
A better-ranked stock in the Medical – Outpatient and Home Healthcare space is Chemed Corp. (CHE - Free Report) , carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Is AMED going up? Or down? Predict to see what others think: Up or Down
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? Last year's market-beating Top 10 portfolio produced 5 double-digit winners. For example, oil and natural gas giant Pioneer Natural Resources and First Republic Bank racked up stellar gains of +44.9% and +44.3% respectively. Now a brand-new list for 2017 has been hand-picked from 4,400 companies covered by the Zacks Rank. See the 2017 Top 10 right now>>